Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib.

MLA

Broege, Aaron, et al. “Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/MTOR Pathway and a Pan-PI3K/MTOR Inhibitor, Gedatolisib.” Cancers, vol. 16, no. 20, Oct. 2024, p. 3520. EBSCOhost, https://doi.org/10.3390/cancers16203520.

APA

Broege, A., Rossetti, S., Sen, A., Menon, A. S., MacNeil, I., Molden, J., & Laing, L. (2024). Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib. Cancers, 16(20), 3520. https://doi.org/10.3390/cancers16203520

Chicago

Broege, Aaron, Stefano Rossetti, Adrish Sen, Arul S. Menon, Ian MacNeil, Jhomary Molden, and Lance Laing. 2024. “Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/MTOR Pathway and a Pan-PI3K/MTOR Inhibitor, Gedatolisib.” Cancers 16 (20): 3520. doi:10.3390/cancers16203520.